Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Definitive Healthcare (DH) Change in Receivables (2020 - 2025)

Definitive Healthcare (DH) has disclosed Change in Receivables for 6 consecutive years, with $18.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 2.93% year-over-year to $18.0 million, compared with a TTM value of -$1.4 million through Dec 2025, up 75.69%, and an annual FY2025 reading of -$1.4 million, up 75.69% over the prior year.
  • Change in Receivables was $18.0 million for Q4 2025 at Definitive Healthcare, up from -$3.5 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $25.7 million in Q4 2022 and bottomed at -$12.2 million in Q2 2024.
  • Average Change in Receivables over 5 years is $803000.0, with a median of -$4.9 million recorded in 2021.
  • The sharpest move saw Change in Receivables skyrocketed 61.43% in 2022, then tumbled 294.82% in 2023.
  • Year by year, Change in Receivables stood at $15.9 million in 2021, then surged by 61.43% to $25.7 million in 2022, then dropped by 27.72% to $18.6 million in 2023, then fell by 5.95% to $17.5 million in 2024, then rose by 2.93% to $18.0 million in 2025.
  • Business Quant data shows Change in Receivables for DH at $18.0 million in Q4 2025, -$3.5 million in Q3 2025, and -$5.5 million in Q2 2025.